ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors
Potential First-In-Class Agent
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
